{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T14:00:14Z","timestamp":1762869614843,"version":"3.37.3"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-023-03555-8","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T12:03:01Z","timestamp":1679572981000},"page":"2629-2637","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identifying the main predictors of urine output in autosomal-dominant polycystic kidney disease (ADPKD) patients taking tolvaptan"],"prefix":"10.1007","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8861-3132","authenticated-orcid":false,"given":"Francisco Jos\u00e9 Borrego","family":"Utiel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Isabel Morales","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurora Polo","family":"Moyano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Roca","family":"Oporto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enoc Merino","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael Esteban","family":"de la Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,23]]},"reference":[{"key":"3555_CR1","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E et al (2012) Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367:2407\u20132418","journal-title":"N Engl J Med"},{"issue":"20","key":"3555_CR2","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","volume":"377","author":"VE Torres","year":"2017","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G et al (2017) Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med 377(20):1930\u20131942","journal-title":"N Engl J Med"},{"key":"3555_CR3","first-page":"860","volume":"287","author":"Y Yamamura","year":"1998","unstructured":"Yamamura Y, Nakamura S, Itoh S et al (1998) OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 287:860\u2013867","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"3555_CR4","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1053\/j.ajkd.2012.08.038","volume":"61","author":"WE Boertien","year":"2013","unstructured":"Boertien WE, Meijer E, Li J, Bost JE, Struck J, Flessner MF, Gansevoort RT, Torres VE (2013) Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort. Am J Kidney Dis 61(3):420\u2013429","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"3555_CR5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1681\/ASN.2013040398","volume":"25","author":"VE Torres","year":"2014","unstructured":"Torres VE, Harris PC (2014) Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. J Am Soc Nephrol 25(1):18\u201332","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"3555_CR6","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.ekir.2020.03.011","volume":"5","author":"RD Perrone","year":"2020","unstructured":"Perrone RD, Chapman AB, Oberdhan D, Czerwiec FS et al (2020) The NOCTURNE randomized trial comparing 2 tolvaptan formulations. Kidney Int Rep 5(6):801\u2013812","journal-title":"Kidney Int Rep"},{"issue":"6","key":"3555_CR7","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.ekir.2020.03.013","volume":"5","author":"RD Perrone","year":"2020","unstructured":"Perrone RD, Chapman AB, Oberdhan D, Czerwiec FS, Sergeyeva O et al (2020) A randomized trial of modified-release versus immediate-release tolvaptan in ADPKD. Kidney Int Rep 5(6):790\u2013800","journal-title":"Kidney Int Rep"},{"issue":"6","key":"3555_CR8","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.ekir.2017.07.004","volume":"2","author":"O Devuyst","year":"2017","unstructured":"Devuyst O, Chapman AB, Shoaf SE, Czerwiec FS, Blais JD (2017) Tolerability of aquaretic-related symptoms following tolvaptan for autosomal dominant polycystic kidney disease: results from TEMPO 3:4. Kidney Int Rep 2(6):1132\u20131140","journal-title":"Kidney Int Rep"},{"key":"3555_CR9","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1681\/ASN.2016040448","volume":"28","author":"O Devuyst","year":"2017","unstructured":"Devuyst O, Chapman AB, Gansevoort RT, Higashihara E, Perrone RD et al (2017) Urine osmolality, response to tolvaptan, and outcome in autosomal dominant polycystic kidney disease: results from the TEMPO 3:4 Trial. J Am Soc Nephrol 28:1592\u20131602","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"3555_CR10","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/ki.2011.119","volume":"80","author":"MV Irazabal","year":"2011","unstructured":"Irazabal MV, Torres VE, Hogan MC, Glockner J et al (2011) Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. Kidney Int 80(3):295\u2013301","journal-title":"Kidney Int"},{"issue":"6","key":"3555_CR11","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1053\/j.ajkd.2014.11.010","volume":"65","author":"WE Boertien","year":"2015","unstructured":"Boertien WE, Meijer E, de Jong PE, ter Horst GJ, Renken RJ et al (2015) Short-term effects of tolvaptan in individuals with autosomal dominant polycystic kidney disease at various levels of kidney function. Am J Kidney Dis 65(6):833\u2013841","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"3555_CR12","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1053\/j.ajkd.2018.09.016","volume":"73","author":"BJ Kramers","year":"2019","unstructured":"Kramers BJ, van Gastel MDA, Boertien WE, Meijer E, Gansevoort RT (2019) Determinants of urine volume in ADPKD patients using the vasopressin V2 receptor antagonist tolvaptan. Am J Kidney Dis 73(3):354\u2013362","journal-title":"Am J Kidney Dis"},{"key":"3555_CR13","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1093\/ckj\/sfaa171","volume":"14","author":"FJ Borrego Utiel","year":"2020","unstructured":"Borrego Utiel FJ, Merino GE (2020) Glomerular filtration rate is the main predictor of urine volume in autosomal dominant polycystic kidney disease patients treated with tolvaptan when daily osmolar excretion is expressed as urinary osmolality\/creatinine ratio. Clin Kidney J 14:1031\u20131033","journal-title":"Clin Kidney J"},{"key":"3555_CR14","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL et al (2009) CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604\u2013612","journal-title":"Ann Intern Med"},{"key":"3555_CR15","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1053\/j.ajkd.2015.10.021","volume":"67","author":"B Bhasin","year":"2016","unstructured":"Bhasin B, Velez JC (2016) Evaluation of polyuria: the roles of solute loading and water diuresis. Am J Kidney Dis 67:507\u2013511","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"3555_CR16","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1159\/000382081","volume":"41","author":"NF Casteleijn","year":"2015","unstructured":"Casteleijn NF, Zittema D, Bakker SJ, Boertien WE et al (2015) Urine and plasma osmolality in patients with autosomal dominant polycystic kidney disease: reliable indicators of vasopressin activity and disease prognosis? Am J Nephrol 41(3):248\u2013256","journal-title":"Am J Nephrol"},{"key":"3555_CR17","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s11255-021-02953-0","volume":"54","author":"FJ Borrego Utiel","year":"2022","unstructured":"Borrego Utiel FJ, Herrera Contreras I, Merino Garc\u00eda E et al (2022) Urinary citrate as a marker of renal function in patients with autosomal dominant polycystic kidney disease. Int Urol Nephrol 54:873\u2013881","journal-title":"Int Urol Nephrol"},{"key":"3555_CR18","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/ki.1989.38","volume":"35","author":"PA Gabow","year":"1989","unstructured":"Gabow PA, Kaehny WD, Johnson AM, Duley IT et al (1989) The clinical utility of renal concentrating capacity in polycystic kidney disease. Kidney Int 35:675\u2013680","journal-title":"Kidney Int"},{"key":"3555_CR19","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1111\/j.1753-4887.2005.tb00151.x","volume":"63","author":"M Ferry","year":"2005","unstructured":"Ferry M (2005) Strategies for ensuring good hydration in the elderly. Nutr Rev 63:S22\u2013S29","journal-title":"Nutr Rev"},{"key":"3555_CR20","first-page":"R148","volume":"272","author":"NS Stachenfeld","year":"1997","unstructured":"Stachenfeld NS, DiPietro L, Nadel ER, Mack GW (1997) Mechanism of attenuated thirst in aging: role of central volume receptors. Am J Physiol 272:R148\u2013R157","journal-title":"Am J Physiol"},{"key":"3555_CR21","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJM198409203111202","volume":"311","author":"PA Phillips","year":"1984","unstructured":"Phillips PA, Rolls BJ, Ledingham JG, Forsling ML, Morton JJ, Crowe MJ, Wollner L (1984) Reduced thirst after water deprivation in healthy elderly men. N Engl J Med 311:753\u2013759","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"3555_CR22","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/nutrit\/nuv051","volume":"73","author":"RJ Maughan","year":"2015","unstructured":"Maughan RJ, Watson P, Shirreffs SM (2015) Implications of active lifestyles and environmental factors for water needs and consequences of failure to meet those needs. Nutr Rev 73(Suppl 2):130\u2013140","journal-title":"Nutr Rev"},{"key":"3555_CR23","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1017\/S0007114511004776","volume":"107","author":"F Manz","year":"2012","unstructured":"Manz F, Johner SA, Wentz A, Boeing H, Remer T (2012) Water balance throughout the adult life span in a German population. Br J Nutr 107:1673\u20131681","journal-title":"Br J Nutr"},{"key":"3555_CR24","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1111\/j.1753-4887.2005.tb00152.x","volume":"63","author":"MN Sawka","year":"2005","unstructured":"Sawka MN, Cheuvront SN, Carter R 3rd (2005) Human water needs. Nutr Rev 63:S30\u2013S39","journal-title":"Nutr Rev"},{"issue":"12","key":"3555_CR25","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.3390\/nu10121928","volume":"10","author":"LE Armstrong","year":"2018","unstructured":"Armstrong LE, Johnson EC (2018) water intake, water balance, and the elusive daily water requirement. Nutrients 10(12):1928","journal-title":"Nutrients"},{"issue":"6","key":"3555_CR26","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.3945\/ajcn.116.137414","volume":"104","author":"AY Rosinger","year":"2016","unstructured":"Rosinger AY, Lawman HG, Akinbami LJ, Ogden CL (2016) The role of obesity in the relation between total water intake and urine osmolality in US adults, 2009\u20132012. Am J Clin Nutr 104(6):1554\u20131561","journal-title":"Am J Clin Nutr"},{"issue":"8","key":"3555_CR27","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.3390\/nu11081923","volume":"11","author":"AI Laja Garc\u00eda","year":"2019","unstructured":"Laja Garc\u00eda AI, Mor\u00e1is-Moreno C, Samaniego-Vaesken ML, Puga AM et al (2019) Influence of water intake and balance on body composition in healthy young adults from Spain. Nutrients 11(8):1923","journal-title":"Nutrients"},{"issue":"6","key":"3555_CR28","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1053\/j.ajkd.2016.07.023","volume":"68","author":"OW Amro","year":"2016","unstructured":"Amro OW, Paulus JK, Noubary F, Perrone RD (2016) Low-osmolar diet and adjusted water intake for vasopressin reduction in autosomal dominant polycystic kidney disease: a pilot randomized controlled trial. Am J Kidney Dis 68(6):882\u2013891","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"3555_CR29","doi-asserted-by":"publisher","first-page":"F46","DOI":"10.1152\/ajprenal.2000.279.1.F46","volume":"279","author":"CA Ecelbarger","year":"2000","unstructured":"Ecelbarger CA, Kim GH, Terris J, Masilamani S et al (2000) Vasopressin-mediated regulation of epithelial sodium channel abundance in rat kidney. Am J Physiol Renal Physiol 279(1):F46-53","journal-title":"Am J Physiol Renal Physiol"},{"key":"3555_CR30","doi-asserted-by":"publisher","first-page":"243S","DOI":"10.1111\/j.1469-445X.2000.tb00029.x","volume":"85","author":"LT Bankir","year":"2000","unstructured":"Bankir LT, Trinh-Trang-Tan MM (2000) Renal urea transporters. Direct and indirect regulation by vasopressin. Exp Physiol 85:243S-252S","journal-title":"Exp Physiol"},{"issue":"3","key":"3555_CR31","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1007\/s10157-017-1475-9","volume":"22","author":"S Minami","year":"2018","unstructured":"Minami S, Hamano T, Iwatani H, Mizui M et al (2018) Tolvaptan promotes urinary excretion of sodium and urea: a retrospective cohort study. Clin Exp Nephrol 22(3):550\u2013561","journal-title":"Clin Exp Nephrol"},{"issue":"2","key":"3555_CR32","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1536\/ihj.13-221","volume":"55","author":"T Imamura","year":"2014","unstructured":"Imamura T, Kinugawa K, Minatsuki S, Muraoka H et al (2014) Urine sodium excretion after tolvaptan administration is dependent upon baseline serum sodium levels: a possible explanation for the improvement of hyponatremia with scarce chance of hypernatremia by a vasopressin receptor antagonist. Int Heart J 55(2):131\u2013137","journal-title":"Int Heart J"},{"issue":"1","key":"3555_CR33","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12882-017-0501-1","volume":"18","author":"S Al Therwani","year":"2017","unstructured":"Al Therwani S, Rosenb\u00e6k JB, Mose FH, Bech JN, Pedersen EB (2017) Effect of tolvaptan on renal water and sodium excretion and blood pressure during nitric oxide inhibition: a dose-response study in healthy subjects. BMC Nephrol 18(1):86","journal-title":"BMC Nephrol"},{"issue":"4","key":"3555_CR34","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1038\/ki.2013.350","volume":"85","author":"SE Shoaf","year":"2014","unstructured":"Shoaf SE, Bricmont P, Mallikaarjun S (2014) Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function. Kidney Int 85(4):953\u2013961","journal-title":"Kidney Int"},{"issue":"Suppl 1","key":"3555_CR35","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1007\/s10557-011-6303-y","volume":"25","author":"M Matsuzaki","year":"2011","unstructured":"Matsuzaki M, Hori M, Izumi T, Asanoi H, Tsutamoto T (2011) Effects of tolvaptan on volume overload in Japanese patients with heart failure: results of a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Cardiovasc Drugs Ther 25(Suppl 1):S19-31","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"3555_CR36","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s12882-017-0686-3","volume":"18","author":"S Al Therwani","year":"2017","unstructured":"Al Therwani S, Malmberg MES, Rosenbaek JB, Bech JN, Pedersen EB (2017) Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study. BMC Nephrol 18(1):268","journal-title":"BMC Nephrol"},{"issue":"Suppl 1","key":"3555_CR37","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1007\/s10557-011-6299-3","volume":"25","author":"SR Kim","year":"2011","unstructured":"Kim SR, Hasunuma T, Sato O, Okada T et al (2011) Pharmacokinetics, pharmacodynamics and safety of tolvaptan, a novel, oral, selective nonpeptide AVP V2-receptor antagonist: results of single- and multiple-dose studies in healthy Japanese male volunteers. Cardiovasc Drugs Ther 25(Suppl 1):S5-17","journal-title":"Cardiovasc Drugs Ther"},{"issue":"2","key":"3555_CR38","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s11255-020-02384-3","volume":"52","author":"G C\u00f4t\u00e9","year":"2020","unstructured":"C\u00f4t\u00e9 G, Asselin-Thompstone L, Mac-Way F, Ren\u00e9 de Cotret P et al (2020) Sodium and urea excretion as determinants of urine output in autosomal dominant polycystic kidney disease patients on V2 receptor antagonists: impact of dietary intervention. Int Urol Nephrol 52(2):343\u2013349","journal-title":"Int Urol Nephrol"},{"issue":"9","key":"3555_CR39","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1093\/ndt\/gfu093","volume":"29","author":"E Higashihara","year":"2014","unstructured":"Higashihara E, Nutahara K, Tanbo M et al (2014) Does increased water intake prevent disease progression in autosomal dominant polycystic kidney disease? Nephrol Dial Transplant 29(9):1710\u20131719","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"3555_CR40","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1253\/circj.CJ-12-1328","volume":"77","author":"T Imamura","year":"2013","unstructured":"Imamura T, Kinugawa K, Minatsuki S, Muraoka H et al (2013) Urine osmolality estimated using urine urea nitrogen, sodium and creatinine can effectively predict response to tolvaptan in decompensated heart failure patients. Circ J 77(5):1208\u20131213","journal-title":"Circ J"},{"issue":"1","key":"3555_CR41","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000381859","volume":"130","author":"H Iwatani","year":"2015","unstructured":"Iwatani H, Kawabata H, Sakaguchi Y, Yamamoto R et al (2015) Urine osmolarity predicts the body weight-reduction response to tolvaptan in chronic kidney disease patients: a retrospective, observational study. Nephron 130(1):8\u201312","journal-title":"Nephron"},{"issue":"6","key":"3555_CR42","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/nep.12406","volume":"20","author":"K Shimizu","year":"2015","unstructured":"Shimizu K, Doi K, Imamura T, Noiri E et al (2015) Ratio of urine and blood urea nitrogen concentration predicts the response of tolvaptan in congestive heart failure. Nephrology (Carlton) 20(6):405\u2013412","journal-title":"Nephrology (Carlton)"},{"issue":"9","key":"3555_CR43","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1253\/circj.CJ-14-0244","volume":"78","author":"T Imamura","year":"2014","unstructured":"Imamura T, Kinugawa K, Fujino T, Inaba T et al (2014) Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure. Circ J 78(9):2240\u20132249","journal-title":"Circ J"},{"issue":"5 Pt 2","key":"3555_CR44","first-page":"F724","volume":"275","author":"TH Kwon","year":"1998","unstructured":"Kwon TH, Frokiaer J, Knepper MA, Nielsen S (1998) Reduced AQP1, 2, and 3 levels in kidneys of rats with CRF induced by surgical reduction in renal mass. Am J Physiol 275(5 Pt 2):F724\u2013F741","journal-title":"Am J Physiol"},{"key":"3555_CR45","doi-asserted-by":"publisher","first-page":"2607928","DOI":"10.1155\/2018\/2607928","volume":"2018","author":"K Czarzasta","year":"2018","unstructured":"Czarzasta K, Cudnoch-Jedrzejewska A, Niemczyk L et al (2018) Effect of chronic kidney disease on changes in vasopressin system expression in the kidney cortex in rats with nephrectomy. Biomed Res Int 2018:2607928","journal-title":"Biomed Res Int"},{"issue":"7","key":"3555_CR46","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/jcph.880","volume":"57","author":"SE Shoaf","year":"2017","unstructured":"Shoaf SE, Chapman AB, Torres VE, Ouyang J, Czerwiec FS (2017) Pharmacokinetics and pharmacodynamics of tolvaptan in autosomal dominant polycystic kidney disease: phase 2 trials for dose selection in the pivotal phase 3 trial. J Clin Pharmacol 57(7):906\u2013917","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"3555_CR47","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1097\/01.ASN.0000089566.28106.F6","volume":"14","author":"JJ Bedford","year":"2003","unstructured":"Bedford JJ, Leader JP, Walker RJ (2003) Aquaporin expression in normal human kidney and in renal disease. J Am Soc Nephrol 14(10):2581\u20132587","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"3555_CR48","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1177\/0091270007307877","volume":"47","author":"SE Shoaf","year":"2007","unstructured":"Shoaf SE, Wang Z, Bricmont P, Mallikaarjun S (2007) Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects. J Clin Pharmacol 47(12):1498\u20131507","journal-title":"J Clin Pharmacol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-023-03555-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-023-03555-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-023-03555-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T16:07:36Z","timestamp":1694621256000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-023-03555-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,23]]},"references-count":48,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["3555"],"URL":"https:\/\/doi.org\/10.1007\/s11255-023-03555-8","relation":{},"ISSN":["1573-2584"],"issn-type":[{"type":"electronic","value":"1573-2584"}],"subject":[],"published":{"date-parts":[[2023,3,23]]},"assertion":[{"value":"29 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The results presented in this article have not been published previously in whole or part, except in abstract format. F.J.B.U. has received lecture fees and travel support from Otsuka. R.E.R. has received grant funding for meeting organizations and travel support from Otsuka.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}